Skip to content

Study · Not a test of the peptide alone · 2013

3 results

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.

Hari Kumar KV, Shaikh A, Prusty P

Diabetes research and clinical practice13 Mar 2013Cited by 80 (Europe PMC)

PMID23490599 (opens in a new tab)DOI10.1016/j.diabres.2013.01.020 (opens in a new tab)PepBankPUB-23490599
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 01HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In new onset type 1 diabetes, the abstract reports that exenatide and sitagliptin added to insulin decreased insulin requirements.

    In plain wordsIn new onset type 1 diabetes, the abstract reports lower insulin needs with exenatide and sitagliptin added to insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseInsulin requirements
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Our data suggest that the addition of exenatide and sitagliptin decreases insulin requirements without increasing endogenous insulin production and hypoglycemic events.
    1 context sentence
    Summary · context
    In this randomized, open label study, we investigated the effect of the addition of exenatide or sitagliptin to insulin in patients with new onset type 1 diabetes.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 02HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In new onset type 1 diabetes, the abstract reports no increase in endogenous insulin production with exenatide and sitagliptin additions.

    In plain wordsIn new onset type 1 diabetes, exenatide and sitagliptin additions did not increase the body's insulin production.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedEndogenous insulin production
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Our data suggest that the addition of exenatide and sitagliptin decreases insulin requirements without increasing endogenous insulin production and hypoglycemic events.
    1 context sentence
    Summary · context
    In this randomized, open label study, we investigated the effect of the addition of exenatide or sitagliptin to insulin in patients with new onset type 1 diabetes.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 03HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialSafety outcome

    In new onset type 1 diabetes, the abstract reports no increase in hypoglycemic events with exenatide and sitagliptin additions.

    In plain wordsIn new onset type 1 diabetes, exenatide and sitagliptin additions did not increase low blood sugar events.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedHypoglycemic events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Our data suggest that the addition of exenatide and sitagliptin decreases insulin requirements without increasing endogenous insulin production and hypoglycemic events.
    1 context sentence
    Summary · context
    In this randomized, open label study, we investigated the effect of the addition of exenatide or sitagliptin to insulin in patients with new onset type 1 diabetes.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01235819

Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus

Command Hospital, Indian = 20Nov 2010 to Sept 2011

Type 1 Diabetes

Trial pageClinicalTrials.govUpdated 27 Jul 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.